PharmaTimes - The latest news in healthcare and life sciences - News RSS
Updated: 2 hours 15 min ago
14/06/2019
The LGR will receive up to $67 million in funding over a five-year period.
14/06/2019
Over a third (36%) of respondents’ staff have asked for faster digital technology systems.
14/06/2019
The drug demonstrated superiority to current standard-of-care to CellCept.
14/06/2019
The sourcebook covers six topics, which were identified as areas where further guidance would be of assistance.
13/06/2019
AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties.
13/06/2019
The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.
13/06/2019
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
13/06/2019
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
13/06/2019
This competition aims to honour those with exceptional talent within the medical and scientific industry, by offering a platform for candidates to share best practice and prove they’ve got the skills to be successful.
12/06/2019
The study is the only active-comparator cardiovascular outcome trial for a DPP-4 inhibitor.
12/06/2019
The data will be presented at the Annual European Congress of Rheumatology (EULAR) on 12-15 June in Madrid, Spain.
12/06/2019
The Vault is a content management system and suite of applications specifically built for life sciences that eradicates the need for multiple programmes.
12/06/2019
The new Chair of the 2019 PharmaTimes Communications Team of the Year executive steering group (ESG) reveals why in-house practitioners and agencies should enter into this unique, industry renowned competition.
11/06/2019
The SMC published advice accepting five new medicines.
11/06/2019
A single 14-day course of PRV-031 was found to significantly delayed the onset and diagnosis of clinical type I diabetes.
11/06/2019
The announcement coincides with the opening of its new preventative healthcare facility, set to open its doors this summer.
11/06/2019
The initial cost of the building was estimated to be £330m.
11/06/2019
The findings "Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
10/06/2019
The biomarker is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market.
Pages
